| Literature DB >> 35819261 |
Russell Moser1, James Annis2, Olga Nikolova3, Cliff Whatcott4, Kay Gurley1, Eduardo Mendez5, Kim Moran-Jones6, Craig Dorrell7, Rosalie C Sears7, Calvin Kuo8, Haiyong Han4, Andrew Biankin4, Carla Grandori9, Daniel D Von Hoff4, Christopher J Kemp1.
Abstract
SIGNIFICANCE: This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer. ©2022 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35819261 PMCID: PMC9481717 DOI: 10.1158/0008-5472.CAN-21-4222
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312